• 목록

• 페이스북 공유
• 트위터 공유
• 구글+ 공유

슬롯커뮤니티 24.rzz283.top 바로가기 슬롯머신 사이트, 뽀빠이놀이터

바다이야기 공략법 87.rzz283.top 사설경정

황금성제주도 80.rzz283.top 온라인게임순위 2018

신야마토 33.rzz283.top 오션파라다이스 다운

양귀비게임설명 63.rzz283.top 황금성3하는곳

다빈치무료릴게임 68.rzz283.top 인터넷바다이야기게임

바다이야기 기프트 전환 64.rzz283.top 오션파라 다이스게임 하는법

체리마스터 공략 9.rzz283.top 황금성

릴게임 신천지 28.rzz283.top 슬롯 프라 그마 틱 무료체험

릴야마토 88.rzz283.top 백경게임 하는곳주소

릴게임손오공게임 20.rzz283.top 핸드폰바다이야기

모바일오션 파라 다이스7 바다이야기 기프트 전환 빠칭코게임 파라 다이스 오션 황금성3게임연타 양귀비 황금성먹튀 야마토2다운로드 sp야마토 일본빠찡꼬 야마토3동영상 슬롯게임 순위 카지노 슬롯머신 잭팟 바다이야기부활 릴게임손오공하는법 슬롯머신 하는법 야마토게임장주소 오락실슬롯머신 꽁머니사이트 빠칭코 황금성게임정보 부산야마토 카지노 슬롯머신 바다이야기 모바일 황금성2 릴게임동영상 알라딘 게임 다운 다빈치릴게임먹튀 인터넷예시게임 오공슬롯 야마토 종합릴게임 바다이야기7 이벤트릴게임 체리마스터 판매 온라인 릴게임 릴황금성 인터넷빠찡꼬 릴게임뜻 릴게임야마토 무료게임다운로드 바다이야기 기프트 전환 릴게임손오공 손오공다운로드 바다이야기 릴게임 88오락실릴게임 인터넷게임사이트 게임바둑이추천 릴게임공략법 골드몽 바다이야기 게임 방법 바다이야기다운로드 골드몽 오리지날게임 슬롯머신무료 피망로우바둑이 안전 검증 릴게임 다빈치다운로드 오공슬롯 슬롯머신 종류 야마토 연타 신천지게임하는방법 야마토릴게임 바다이야기 파일 pc릴게임 황금성 다운 릴게임 무료머니 무료야마토게임 슬롯머신 기계 구입 바다이야기먹튀신고 온라인백경 황금성 프라그마틱무료메타2 온라인릴게임 먹튀 검증 슬롯머신 잭팟 체리게임주소 야마토온라인주소 릴게임 오션파라다이스 릴게임 다운로드 바다이야기 상어 황금성 제주도 바다이야기배당 야마토3 강원랜드슬롯머신 슬롯머신 코딩 오리 지날야마토2게임 중고게임기매매 인터넷신천지 오리자날 양귀비 황금성 무료머니 야마토게임공략 법 무료충전 릴 게임 온라인 릴게임 손오공 오션슬롯먹튀 백경게임 릴게임 일본야마토게임 바다이야기 조작 야마토 릴게임 바다이야기 예시 PC 슬롯 머신 게임 바다이야기 게임 방법 오션릴게임 야마토연타 체리마스터 다운 손오공 온라인 게임 슬롯 머신 html 오리지날 야마토 릴야마토 온라인릴게임 바다이야기pc버전다운 슬롯머신 원리 강원랜드게임종류 슬롯 무료스핀구매 도그하우스 하는법 릴게임 무료머니 잭팟 슬롯게임 무료 알라딘릴게임 신천지다운로드 야마토2다운로드 777 잭팟 바다이야기 꽁 머니 환전 슬롯머신 프로그램 우주전함야마토먹튀 This article was released as Pharm Edaily Premium Content on June 12, 2025, at 7:36 AM.


[Seungkwon kim, Edaily Reporter] Shares of several South Korean biotech and pharmaceutical companies surged Tuesday amid news of ownership changes and clinical trial expectations.
Adbiotech, a veterinary vaccine and supplement company, soared by the daily upper limit f야마토 동영상
or the third consecutive trading day. Shares rose 29.88% (965 won) to close at 4,195 won, following strong buy-side momentum from market open.
The rally comes after the company disclosed on 스탁시티
June 9 that OcuPhi BioM (OQP BioM) would become its largest shareholder through a 28 billion won third-party allotment capital increase.



Adbiotech (KG ze농심홀딩스 주식
roin)



OQP BioM is a biotech firm developing the ovarian cancer immunotherapy candidate “Oregovomab.” Market expectations appear to be linked to a potential바다이야기
restart of the drug’s development.

Oregovomab was initially acquired in 2020 by South Korean firm Diarc (now Hurim A-Tech) from Canada’s OncoQuest for about 375.1 billion won. Th강세주
e drug changed hands multiple times, eventually landing with CanaraBio (now HyunDai Feed), which later suspended its global Phase 3 clinical trials following regulatory recommendations.
CanaraBio went into complete capital impairment after writing off nearly 150 billion won in intangible assets related to Oregovomab, leading to a delisting crisis.
Further controversy surrounds both CanaraBio and OQP BioM, as multiple executives face ongoing criminal trials over alleged stock manipulation schemes. Prosecutors claim they used news surrounding the immunotherapy drug to inflate share prices and gain illicit profits exceeding 700 billion won.
In July 2024, Seoul Southern District Prosecutors indicted a group for gaining about 63.1 billion won through such schemes. These developments have raised significant investor concerns.
In June 2023, the CEO of OQP BioM was arrested on charges of securities fraud and obstruction of business, an incident linked to the high-profile Edison Motors stock manipulation case. At least three others connected to CanaraBio’s network were also detained.
A biotech industry official warned retail investors to exercise caution, noting that CanaraBio once traded above 170,000 won before collapsing to penny-stock levels and facing delisting.



MediPost (KG zeroin)



“Retail investors should be extra careful, especially now that the government is cracking down on such stock manipulation,” the source said.

Meanwhile, GenNBio, another biotech company facing imminent delisting, saw its shares surge by 195.24% to close at 62 won on the third day of its liquidation trading. The stock had plunged 90.75% on the first day of delisting trades.
GenNBio was delisted after failing to resolve auditor opinion issues for its 2023 and 2024 fiscal years. The Korea Exchange (KRX) finalized the delisting decision on June 4. The stock will be traded on a liquidation basis until June 17, with final delisting set for June 18.
Such rapid gains are typically attributed to speculative short-term traders entering after trading resumes, often seen as irregular market behavior.
MediPost also ended the day up 13% at 11,600 won. The gain comes as the company prepares to submit an Investigational New Drug (IND) application for a U.S. Phase 3 clinical trial of its umbilical cord blood-derived stem cell therapy “Cartistem” later this year. The trial could begin by late 2024 or early 2025.
Lastly, GC Genome, a genetic testing affiliate of GC Pharma, closed its first day on the Kosdaq market with a 5.71% gain at 11,100 won slightly above its IPO price of 10,500 won. The stock had briefly surged 44.57% during intraday trading before giving up most of its gains.
GC Genome currently provides over 300 genetic testing services to more than 900 hospitals and clinics.
김승권 (peace@edaily.co.kr)